Year: 2019

 Geneva, Switzerland and Boston, MA –December 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday  December 9, 2019.  ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results. Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134.  A webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website...

BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of an aggregate of 25,300 stock options and 4,150 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of December 2, 2019. The stock options and restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).The stock options have an exercise price of $17.94 per share and vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee’s continued service...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) — Japan Smaller Capitalization Fund, Inc. (NYSE: JOF) (the “Fund”) announced that it would make an ordinary income distribution of $0.2703 per share, a short-term capital gains distribution of $0.1259 per share, and a long-term capital gains distribution of $0.3464 per share, payable on December 27, 2019 to shareholders of record on December 18, 2019. The ex-dividend date will be December 17, 2019.The amounts and sources of distributions reported in this press release are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the entirety of its fiscal year and may be subject to changes based on tax regulations. The Fund intends to send a Form...

EDMONTON, Alberta, Dec. 06, 2019 (GLOBE NEWSWIRE) — John Babic, President and CEO of Dalmac Energy Inc. (“Dalmac”) (TSX Venture “DAL”) announces effective December 3, 2019, Su Chun has resigned as the chief financial officer of Dalmac Energy Inc. Dalmac wishes to thank Ms. Chun for her contributions and efforts and wishes her well in her future endeavours.

– Today’s AL002 presentation showcases the first data in humans with a TREM2 antibody– AL002 was generally safe and well-tolerated in healthy volunteers– Reduced CSF sTREM2 level demonstrates target engagementSOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported safety and biomarker data from the single ascending dose (SAD) phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers. AL002 is a monoclonal antibody intended to enhance the activity of TREM2 and is being developed by Alector for the treatment of Alzheimer’s disease in collaboration with its partner AbbVie. The data were presented today at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) meeting...

OMAHA, Neb., Dec. 06, 2019 (GLOBE NEWSWIRE) — On December 2, 2019, Craig S. Allen informed America First Multifamily Investors, L.P. (NASDAQ: ATAX) (the “Partnership” or “ATAX”) of his intent to retire and leave the Partnership in his capacity as its Chief Financial Officer on December 31, 2019. Mr. Allen has held his position since 2015. Mr. Allen and the Partnership have entered into a Consulting Agreement to allow Mr. Allen to assist the Partnership during its transition to a permanent replacement.On December 6, 2019, the Board of Managers of Greystone AF Manager LLC, the general partner of the general partner of the Partnership, appointed Jesse A. Coury, the Partnership’s current Corporate Controller, to serve as the Partnership’s interim Chief Financial Officer, effective on January 1, 2020. Mr. Coury will serve in this capacity...

ST. JOHN’S, Terre-Neuve-et-Labrador, 06 déc. 2019 (GLOBE NEWSWIRE) — Fortis Inc. (« Fortis » ou la « Société ») (TSX:FTS) (NYSE:FTS) a annoncé aujourd’hui l’émission d’un total de 1 726 500 actions ordinaires (les « actions ordinaires ») à la suite de l’exercice de l’option de surallocation (l’« option de surallocation ») qu’elle avait octroyée à un syndicat de preneurs fermes dirigé par Scotia Capitaux Inc., Marchés des capitaux CIBC et RBC Marchés des capitaux dans le cadre du placement par voie de prise ferme précédemment annoncé (le « placement par voie de prise ferme »). L’exercice de l’option de surallocation a généré un produit brut de 90 M$ CA pour Fortis; si on ajoute le résultat du placement par voie de prise ferme, le produit brut total s’élève à 690 M$ CA.La Société affectera le produit net à son plan d’immobilisations,...

APRIL: Purchase agreement signed for the sale of Axeria IARDThe APRIL Group announces today the signing of a share purchase agreement for the sale of Axeria IARD, a risk-carrying subsidiary specialised in Property & Casualty insurance.The share purchase agreement, signed with Watford Holdings Ltd. (“Watford”), relates to the sale by APRIL Group, and the acquisition by Watford, of 100% of the capital stock of Axeria IARD.This transaction, subject to regulatory approval, is in line with the new development strategy initiated by the APRIL Group to refocus around brokerage in five key markets (individual health and personal protection, professionals and VSEs, loan insurance, international health and property and casualty niches), as announced on 18 March 2019. Axeria IARD recorded sales of €139.9 million in 2018.The closing...

APRIL : Signature d’un contrat d’acquisition en vue de la cessiond’Axeria IARDLe groupe APRIL annonce aujourd’hui la conclusion d’un contrat d’acquisition pour la cession d’Axeria IARD, filiale de portage de risque du groupe spécialisée dans l’assurance dommages.Le contrat d’acquisition, signé avec Watford Holdings Ltd. (« Watford »), porte sur la vente par le groupe APRIL et l’acquisition par Watford de 100% du capital d’Axeria IARD.Cette opération, soumise à approbation réglementaire, s’inscrit dans la continuité de la stratégie de recentrage et de développement initiée par le groupe APRIL autour des activités de courtage sur cinq marchés phares (la santé et la prévoyance du particulier, des professionnels et des TPE, l’assurance emprunteur, la santé internationale et les niches dommage), annoncée le 18 mars 2019. Axeria IARD a généré...